183 related articles for article (PubMed ID: 38313799)
21. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
22. The role of
Hou H; Sun D; Zhang X
Cancer Cell Int; 2019; 19():216. PubMed ID: 31440117
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the new TNM-staging system for thymic malignancies: impact on indication and survival.
Ried M; Eicher MM; Neu R; Sziklavari Z; Hofmann HS
World J Surg Oncol; 2017 Dec; 15(1):214. PubMed ID: 29197400
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.
Binju M; Padilla MA; Singomat T; Kaur P; Suryo Rahmanto Y; Cohen PA; Yu Y
Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):371-378. PubMed ID: 30423357
[TBL] [Abstract][Full Text] [Related]
25. Salvage surgery for advanced non-small cell lung cancer after targeted therapy: A case series.
Song W; Di S; Liu J; Fan B; Zhao J; Zhou S; Chen S; Dong H; Yue C; Gong T
Thorac Cancer; 2020 Apr; 11(4):1061-1067. PubMed ID: 32107870
[TBL] [Abstract][Full Text] [Related]
26. EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.
Tulchinsky E; Demidov O; Kriajevska M; Barlev NA; Imyanitov E
Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):29-39. PubMed ID: 30419315
[TBL] [Abstract][Full Text] [Related]
27. The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance.
Loret N; Denys H; Tummers P; Berx G
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31213009
[TBL] [Abstract][Full Text] [Related]
28. Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.
Li MSC; Mok KKS; Mok TSK
Ann Transl Med; 2023 Aug; 11(10):358. PubMed ID: 37675321
[TBL] [Abstract][Full Text] [Related]
29. Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer.
Riquelme I; Letelier P; Riffo-Campos AL; Brebi P; Roa JC
Int J Mol Sci; 2016 Mar; 17(3):424. PubMed ID: 27011182
[TBL] [Abstract][Full Text] [Related]
30. Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments.
Tang YL; Li DD; Duan JY; Sheng LM; Wang X
World J Gastroenterol; 2023 Feb; 29(6):926-948. PubMed ID: 36844139
[TBL] [Abstract][Full Text] [Related]
31. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
[TBL] [Abstract][Full Text] [Related]
32. The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer.
Lan H; Yuan J; Zeng D; Liu C; Guo X; Yong J; Zeng X; Xiao S
Front Genet; 2021; 12():693259. PubMed ID: 34512721
[TBL] [Abstract][Full Text] [Related]
33. [The expression of MRP, GST-pi, Topo IIalpha and COX-2 in epithelial ovarian cancer and its relationship to drug resistance and prognosis].
Cao DY; Shen K; Yang JX; Guan J
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(25):1738-41. PubMed ID: 17919376
[TBL] [Abstract][Full Text] [Related]
34. Resistance and recurrence of malignancies after CAR-T cell therapy.
Zeng W; Zhang P
Exp Cell Res; 2022 Jan; 410(2):112971. PubMed ID: 34906583
[TBL] [Abstract][Full Text] [Related]
35. Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance.
Khattak M; Larkin J
World J Urol; 2014 Feb; 32(1):19-29. PubMed ID: 23297098
[TBL] [Abstract][Full Text] [Related]
36. The origin of gastric cancer stem cells and their effects on gastric cancer: Novel therapeutic targets for gastric cancer.
Yang Y; Meng WJ; Wang ZQ
Front Oncol; 2022; 12():960539. PubMed ID: 36185219
[TBL] [Abstract][Full Text] [Related]
37. Non-coding RNA in drug resistance of gastric cancer.
Luo YJ; Huang QM; Ren Y; Liu ZL; Xu CF; Wang H; Xiao JW
World J Gastrointest Oncol; 2019 Nov; 11(11):957-970. PubMed ID: 31798777
[TBL] [Abstract][Full Text] [Related]
38. From platinum compounds to targeted therapies in advanced thoracic malignancies.
Jakopovic M; Thomas A; Lopez-Chavez A
Anticancer Res; 2014 Jan; 34(1):477-82. PubMed ID: 24403504
[TBL] [Abstract][Full Text] [Related]
39. Advancement in research and therapy of
Tao J; Sun D; Dong L; Zhu H; Hou H
Cancer Cell Int; 2020; 20():492. PubMed ID: 33061844
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer.
Mao C; Zeng X; Zhang C; Yang Y; Xiao X; Luan S; Zhang Y; Yuan Y
Front Cell Dev Biol; 2021; 9():612451. PubMed ID: 33644048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
